Last summer I recommended buying LEAPS, or long-term call options, on Broadcom (NSDQ: AVGO) and Lam Research (NSDQ: LRCX). At the time, both stocks appeared undervalued, according to my IDEAL stock-rating system, and since then each has appreciated roughly 40%, confirming my analysis. I still like both companies, but… Read More

Of the three under-followed stocks we chose, only one faltered, leaving us with a total 43% gain. Read More

The Republican healthcare plan was the last straw for two struggling biotech holdings. Read More

Helmerich & Payne’s machines are in demand as technology drives the next stage of the shale boom. Read More

It’s time to capitalize on Trump Disruption, and we know just how to do it. Read More

It’s time to clean out three option plays to make room for new strategies as the market dynamic changes. I am recommending closing out the HCA June 2017 $80 and the Molina June 2017 $55 straddles along with the Biotelemetry May 2017 $21 protective put. Aside from the individual company-related… Read More

The market’s reaction to a fourth-quarter earnings report has likely provided a trading opportunity on a microcap biotech company with a potentially explosive future. Synergy Pharmaceuticals (NSDQ: SGYP), a biotech company specializing in drugs for gastrointestinal conditions, is making the leap from development-stage company to one with a potential… Read More